Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients

Clin Nucl Med. 1992 Jan;17(1):41-4. doi: 10.1097/00003072-199201000-00012.


Single intravenous injections of 30 to 35 mCi (1,110 to 1,295 MBq) of Re-186(Sn)HEDP previously have been shown to result in palliation of painful skeletal metastases from prostate cancer. There are no reports of patients receiving repetitive Re-186(Sn)HEDP therapy. We have followed two such patients who received multiple (five to seven) injections of Re-186(Sn)HEDP at 2-month intervals. Each experienced a sustained decrease in both pain and analgesic intake. The only evident clinical or biochemical toxicity was a mild progressive decline in their total platelet counts.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / physiopathology
  • Adenocarcinoma / secondary
  • Aged
  • Bone Neoplasms / physiopathology*
  • Bone Neoplasms / secondary
  • Etidronic Acid / therapeutic use*
  • Humans
  • Male
  • Organometallic Compounds / therapeutic use*
  • Pain, Intractable / therapy*
  • Palliative Care / methods*
  • Platelet Count
  • Prostatic Neoplasms / pathology


  • Organometallic Compounds
  • rhenium-186(tin)etidronate
  • Etidronic Acid